Abstracts tagged "prevention"

Abstract Number: 0114 • ACR Convergence 2021
The Safety Profile of SARS-CoV-2 Vaccines Among Patients with Immune-Mediated Rheumatic Diseases
Jose A Gomez-Puerta¹, Núria Sapena², Juan C Sarmiento-Monroy³, Ana Belén Azuaga¹, Virginia Ruiz-Esquide², Beatriz Frade-Sosa², Marta Bassas², Rosa Morlà², Andrés Ponce², Juan D Cañete¹, Julio Ramirez², Anna Villella⁴, Antoni Trilla⁴ and Raimon Sanmarti⁵, ¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, ²Rheumatology Department, Hospital Clínic, Barcelona, Spain, ³Hospital Clinic Barcelona, Barcelona, Spain, ⁴Department of Preventive Medicine and Epidemiology, Hospital Clínic, Barcelona, Spain, ⁵Hospital Clínic de Barcelona, Barcelona, Spain
Background/Purpose: The best strategy for the prevention of SARS-CoV-2 infection is vaccination. Both mRNA and vector vaccines have demonstrated a satisfactory safety profile in general…
Abstract Number: 0116 • ACR Convergence 2021
COVID-19 mRNA Vaccine Side Effects Among Individuals with Rheumatic Disease
Kaleb Michaud¹, Adam Cornish², Alison Freifeld¹, Patricia Katz³ and Kristin Wipfler², ¹University of Nebraska Medical Center, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Over 135 million Americans were fully vaccinated to COVID-19 by June 2021, yet there was a paucity of data on side effects for those…
Abstract Number: 0141 • ACR Convergence 2021
Who Gets Influenza Vaccinations Prior to and After a Diagnosis of RA? Results from the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois¹, Ines Colmegna³, Carol Hitchon⁴, Louis Bessette⁵, Glen Hazlewood⁶, Carter Thorne⁷, Janet Pope⁸, Gilles Boire⁹, Diane Tin¹⁰, Edward Keystone¹¹, Vivian Bykerk¹², Susan Bartlett¹ and CATCH Investigators¹³, ¹McGill University, Montréal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York, NY, ¹³Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: Annual influenza vaccination is recommended for adults with RA, but remains low in established RA. We examined influenza vaccination coverage in the year prior…
Abstract Number: 0461 • ACR Convergence 2021
Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria
Meagan Chriswell¹, Jennifer Seifert², Michelle Bloom³, Cliff Rims⁴, Marie Feser⁵, Kevin Deane⁶, Jill Norris⁷, Eddie James⁸, Jane Buckner⁹, William Robinson¹⁰, V. Michael Holers¹¹ and Kristine Kuhn¹², ¹UC Denver SOM, Denver, CO, ²University of Colorado School of Medicine, Littleton, CO, ³Stanford University, Redwood City, CA, ⁴Benaroya Research Institute, Seattle, WA, ⁵University of Colorado Denver, Aurora, CO, ⁶University of Colorado Denver, Denver, CO, ⁷Colorado School of Public Health, Aurora, CO, ⁸Benaroya Research Institute at Virginia Mason, Monroe, WA, ⁹Benaroya Research Institute at Virginia Mason, Seattle, WA, ¹⁰Stanford University, Palo Alto, CA, ¹¹University of Colorado, Denver, CO, ¹²University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Circulating autoantibodies like ACPA frequently develop years before symptoms of RA, during which the individual is at-risk for disease. Several lines of evidence suggest…
Abstract Number: 0876 • ACR Convergence 2021
Antibody Response in Patients with Systemic Lupus Erythematosus After a Two-dose Regimen with SARS-CoV-2 Vaccines (Preliminary Results)
Emilie Stavnsbjerg Larsen¹, Anna Christine Nilsson², Ulrik Stenz Justesen¹, Anne Voss³ and Isik Somuncu Johansen⁴, ¹Odense University Hospital, Odense C, Denmark, ²Odense Universitets Hospital, Odense C, Denmark, ³Department of Rheumatology, Odense University Hospital, Odense C, Denmark, ⁴Odense University Hospital, Odense, Denmark
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) often receive immunosuppressive treatment for many years, resulting in higher risk of infections, including COVID-19, and infections may…
Abstract Number: 0957 • ACR Convergence 2021
Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial
Jill Hahn¹, Nancy Cook², Erik Alexander³, Sonia Friedman³, Vadim Bubes³, Joseph Walter³, Gregory Kotler³, I-Min Lee³, JoAnn Manson³ and Karen Costenbader⁴, ¹Harvard T.H. Chan School of Public Health, Boston, MA, ²Brigham and Womens' Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: In observational studies, vitamin D has been inconsistently associated with reduced risk of several autoimmune diseases, and a large randomized, controlled trial has been…
Abstract Number: 1077 • ACR Convergence 2021
Effectiveness of Non-Pharmacological Interventions to Promote Work Participation of People with Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Regression Analysis
Maarten Butink¹, Casper Webers², Suzanne Verstappen³, Robin Christensen⁴, Louise Falzon⁵, Johannes Bijlsma⁶, Gerd Burmester⁷ and Annelies Boonen², ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+); Department of Social Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht, Limburg, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands, ³School of Social Sciences, The University of Manchester, Manchester, United Kingdom, ⁴Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Copenhagen, Denmark, ⁵Center for Personalized Health, Northwell Health, New York City, NY, ⁶Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁷Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Despite improvements in the treatment of rheumatic and musculoskeletal diseases (RMDs), reduced work participation persists when compared to the general population. A Task Force…
Abstract Number: 1139 • ACR Convergence 2021
Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements
Muntarin Karim¹, lorien ahn², Jordan Thompson¹, Christina Downey³, Lorena Salto⁴ and Karina Torralba⁵, ¹Loma Linda University, Redlands, CA, ²loma linda university medical center, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University Health, Loma Linda, CA, ⁵Division of Rheumatology, Department of Medicine, Loma Linda University Healthcare, Loma Linda, CA
Background/Purpose: Osteoporosis causes significant morbidity and mortality in the elderly. Despite the benefits of treatment, < 25% of elderly patients who fracture receive treatment. A…
Abstract Number: 1554 • ACR Convergence 2021
COVID-19 Vaccine Hesitancy Among Patients with Rheumatic and Other Diseases
Valeria Valerio¹, Emmanouil Rampakakis², Marie Hudson³, Sasha Bernatsky³, Elizabeth M. Hazel³ and Ines Colmegna⁴, ¹Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ²JSS Medical Research, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴The Research Institute of the McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Vaccination is fundamental to reduce COVID-19 risk and its complications. Vaccine hesitancy is a threat to COVID-19 vaccination uptake. We assessed the frequency of…
Abstract Number: 1557 • ACR Convergence 2021
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
Ana Medeiros-Ribeiro¹, Nadia Aikawa¹, Carla Gonçalves Schahin Saad¹, Emily Figueiredo Vieira Neves Yuki¹, Tatiana do Nascimento Pedrosa¹, Solange Fusco¹, Priscila Rojo¹, Rosa Pereira¹, Samuel Shinjo¹, Danieli Andrade¹, Percival Sampaio-Barros¹, Carolina Ribeiro¹, Giordano Deveza¹, Victor Adriano de Oliveira Martins¹, Clovis Artur Silva¹, Marta Lopes¹, Alberto Duarte¹, Leila Antonangelo¹, Ester Sabino¹, Esper Kallas¹, Sandra Gofinet Pasoto² and Eloisa Bonfá¹, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital das Clinicas de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Brazil is among the countries with the highest numbers of confirmed cases and deaths by COVID-19. CoronaVac (SARS-CoV-2 inactivated vaccine) has been largely used…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 1711 • ACR Convergence 2021
Increasing Preeclampsia Knowledge in SLE with a Specific Educational Tool: Preliminary Results
Joo Young (Esther) Lee¹, Arielle Mendel², Isabelle Malhamé², Sasha Bernatsky¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Pregnant women with systemic lupus erythematosus (SLE) are at high risk of preeclampsia, leading to substantial maternal and fetal morbidity. Aspirin reduces preeclampsia risk…
Abstract Number: 1777 • ACR Convergence 2020
Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Isabell Haase¹, Matthias Schneider¹, Ralph Brinks¹ and Rebecca Fischer-Betz¹, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Women with Systemic Lupus Erythematosus (SLE) face a higher risk of pre-eclampsia, especially those with additional risk factors. Low dose aspirin (LDA) is known…
Abstract Number: 1977 • ACR Convergence 2020
Delivering Fracture Prevention Through Telemedicine: A Process Evaluation
Karla Miller¹, Melissa Steffen², Aaron Seaman², Zachary Anderson¹, Janiel Green¹, Shardool Patel¹, Shylo Wardyn² and Samantha Solimeo², ¹Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ²Iowa VA Healthcare System, Iowa City, IA
Background/Purpose: Guidelines recommend osteoporosis screening using dual-energy X-ray absorptiometry (DXA) in men and women at risk for osteoporosis, but screening remains low, especially in men…
Abstract Number: 0109 • ACR Convergence 2020
Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?
Eileen Rife¹, Emejuaiwe Nkechinyere² and Jose Leon de la Rocha³, ¹Louisiana State University, Metairie, LA, ²Department of Veterans Affairs, New Orleans, LA, ³Louisiana State University, Auburn, AL
Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).Methods: We queried the electronic database of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].